11.2 Capital

11.2 Capital operates as a specialized deep-tech venture capital firm based in New York, focusing on the intersection of artificial intelligence, digital health, and cybersecurity since its 2018 founding. The firm distinguishes itself through an unusual dual-stage investment approach, participating in both pre-seed rounds for emerging startups and Series B+ funding for more mature companies, allowing them to maintain relationships with portfolio companies across multiple growth phases. Their bioengineering focus sets them apart in a crowded VC market, as few firms possess the technical expertise to evaluate complex biotech and medtech opportunities at the intersection of AI and life sciences. The firm's investment strategy appears centered on identifying companies that leverage artificial intelligence to solve fundamental problems in healthcare delivery, medical devices, and biotechnology applications. While 11.2 Capital maintains a relatively low public profile compared to larger institutional funds, industry observers note their selective approach to deal sourcing and emphasis on technical due diligence. The firm's New York location positions them strategically within the growing East Coast tech ecosystem, particularly for digital health companies that benefit from proximity to major medical institutions and regulatory expertise. Their portfolio construction suggests a focus on companies developing proprietary technology platforms rather than incremental software solutions, reflecting their deep-tech thesis. The cybersecurity component of their investment mandate typically intersects with their healthcare focus, targeting companies developing security solutions for medical data, IoT devices in healthcare settings, and compliance-focused enterprise software. Since inception, 11.2 Capital has operated with a concentrated portfolio approach, suggesting they prefer to make meaningful investments in fewer companies rather than pursuing a spray-and-pray strategy common among early-stage funds.